GBT News

US IPO Market Contracts as Returns Slump in the Third Quarter The IPO market slowed in the 3Q 2015 to 34 deals, down 43% year-over-year, hurt by the broad market sell-off and specific sector conditions, including a near absence of tech and energy issuance. In addition, a significant number of IPOs were pulled or delayed due to market conditions or acquisitions. For the...read more

Global Blood Therapeutics became the fifth IPO of 2015 to pop more than 100% on its first day. Year-to-date, 130 IPOs have raised $22 billion, or 31% fewer IPOs than last year and 45% less capital. Even with six postponements this month, ...read more

Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, raised $120 million by offering 6.0 million shares at $20, above the range of $16 to $18. Global Blood Therapeutics plans to list on the Nasdaq under the symbol GBT. Morgan Stanley and Goldman Sachs acted as lead managers on the deal. ...read more

It's the final push for US IPOs before a four-week lull that should end in mid-September. Five IPOs are on the calendar this week, plus two blank check companies. Sickle cell biotech Global Blood Therapeutics could attract investor attention, while investment bank Houlihan Lokey boasts a...read more